Baili Tianheng announced that BL - B01D1, an innovative biopharmaceutical independently developed by the company, recently received the “Drug Clinical Trial Approval Notice” from the State Drug Administration, agreeing to conduct clinical trials of its single drug in patients with advanced solid tumors. This product is a subcutaneous preparation developed on the basis of lenconylontuzumab already marketed by the company. Drugs need to complete clinical trials and go through review and approval before they can be marketed, and there is uncertainty about research and development.

Baili Tianheng announced that BL - B01D1, an innovative biopharmaceutical independently developed by the company, recently received the “Drug Clinical Trial Approval Notice” from the State Drug Administration, agreeing to conduct clinical trials of its single drug in patients with advanced solid tumors. This product is a subcutaneous preparation developed on the basis of lenconylontuzumab already marketed by the company. Drugs need to complete clinical trials and go through review and approval before they can be marketed, and there is uncertainty about research and development.